193 related articles for article (PubMed ID: 29088918)
1. The application of molecular topology for ulcerative colitis drug discovery.
Bellera CL; Di Ianni ME; Talevi A
Expert Opin Drug Discov; 2018 Jan; 13(1):89-101. PubMed ID: 29088918
[TBL] [Abstract][Full Text] [Related]
2. Latest advances in molecular topology applications for drug discovery.
Zanni R; Galvez-Llompart M; García-Domenech R; Galvez J
Expert Opin Drug Discov; 2015; 10(9):945-57. PubMed ID: 26134383
[TBL] [Abstract][Full Text] [Related]
3. Molecular topology: a strategy to identify novel compounds against ulcerative colitis.
Gálvez-Llompart M; Recio MC; García-Domenech R; Gálvez J
Mol Divers; 2017 Feb; 21(1):219-234. PubMed ID: 27734189
[TBL] [Abstract][Full Text] [Related]
4. What place does molecular topology have in today's drug discovery?
Zanni R; Galvez-Llompart M; Garcia-Domenech R; Galvez J
Expert Opin Drug Discov; 2020 Oct; 15(10):1133-1144. PubMed ID: 32496823
[TBL] [Abstract][Full Text] [Related]
5. Molecular topology as a novel approach for drug discovery.
Gálvez J; Gálvez-Llompart M; García-Domenech R
Expert Opin Drug Discov; 2012 Feb; 7(2):133-53. PubMed ID: 22468915
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationship: promising advances in drug discovery platforms.
Wang T; Wu MB; Lin JP; Yang LR
Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617
[TBL] [Abstract][Full Text] [Related]
7. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery.
Speck-Planche A; Cordeiro MN
Expert Opin Drug Discov; 2015 Mar; 10(3):245-56. PubMed ID: 25613725
[TBL] [Abstract][Full Text] [Related]
8. On the contribution of molecular topology to drug design and discovery.
Gálvez J; García-Doménech R
Curr Comput Aided Drug Des; 2010 Dec; 6(4):252-68. PubMed ID: 20883200
[TBL] [Abstract][Full Text] [Related]
9. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
10. Molecular Topology and Other Promiscuity Determinants as Predictors of Therapeutic Class - A Theoretical Framework to Guide Drug Repositioning?
Morales JF; Alberca LN; Chuguransky S; Di Ianni ME; Talevi A; Ruiz ME
Curr Top Med Chem; 2018; 18(13):1110-1122. PubMed ID: 30068278
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive and biologic therapy for ulcerative colitis.
Ardizzone S; Cassinotti A; de Franchis R
Expert Opin Emerg Drugs; 2012 Dec; 17(4):449-67. PubMed ID: 23163556
[TBL] [Abstract][Full Text] [Related]
12. Ulcerative Colitis: Update on Medical Management.
Iskandar HN; Dhere T; Farraye FA
Curr Gastroenterol Rep; 2015 Nov; 17(11):44. PubMed ID: 26386686
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
14. QSAR studies in the discovery of novel type-II diabetic therapies.
Abuhammad A; Taha MO
Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
[TBL] [Abstract][Full Text] [Related]
15. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
Wang T; Yuan XS; Wu MB; Lin JP; Yang LR
Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095
[TBL] [Abstract][Full Text] [Related]
16. [Biological agents in ulcerative colitis. When to prescribe].
Barreiro-de Acosta M
Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():36-42. PubMed ID: 25443225
[TBL] [Abstract][Full Text] [Related]
17. Golimumab: clinical update on its use for ulcerative colitis.
Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
[TBL] [Abstract][Full Text] [Related]
18. Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis.
Bilsborough J; Fiorino MF; Henkle BW
Expert Opin Drug Discov; 2021 May; 16(5):567-577. PubMed ID: 33245673
[No Abstract] [Full Text] [Related]
19. Investigational cytokine-targeted therapies for ulcerative colitis.
Monteleone G; Pallone F; Caprioli F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1123-32. PubMed ID: 23802627
[TBL] [Abstract][Full Text] [Related]
20. Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework?
Dobchev D; Karelson M
Expert Opin Drug Discov; 2016 Jul; 11(7):627-39. PubMed ID: 27149299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
